jump to content jump to footer

Categories:

Number of Clinical Trials in Oncology has increased strongly during the last 10 years
Cancer cases and cancer related deaths continue to increase globally. While new cancer therapies are being identified offering new options for…
New TNM- and RADS-Classification in mint Lesion
With the aid of various clinical reading templates, mint Lesion provides context-specific support in the application of established radiological…
New mint Lesion 3.4 Software presented at RSNA 2017
With mint Lesion 3.4, reproducible assessment and structured reporting of significant image observations are easier than ever. Numerous improvements…
ESOI/EORTC Workshop in Barcelona: Participants practice tumour response assessment using mint Lesion™
The autumn workshop of the European Society of Oncological Imaging (ESOI) and the European Organisation for Research and Treatment of Cancer (EORTC)…
Mint Medical showcases MSK-Prototype at IMR 2017 in Hamburg
Mint Medical was one of the sponsors of the first Intensive course Musculoskeletal Radiology (IMR) which took place on September 8th and 9th 2017 in…
A look ahead with mint Lesion 3.3
Mint Medical is pleased to announce the recent release of their software product version 3.3 of mint Lesion™ which was completed during recent weeks.…
New iRECIST Oncologic Response Criteria already in clinical use at the University Medical Center – Tübingen, Germany
Shortly following the release of the new iRECIST- oncologic response criteria (Lancet Oncology, March 2017) the University Medical Center in Tübingen,…
Mrs. Kelie Luby joins Mint Medical's team
Mrs. Kelie Luby will join Mint Medical’s team from January 2017 as new Vice President Clinical Trials Software and will be introduced at the upcoming…
Novel oncologic therapy response criteria (iRECIST and more)
Advances in oncology therapies, such as novel immune-related agents, require adapted and refined criteria and guidelines for the assessment and…